International Journal of Science and Research (IJSR)

International Journal of Science and Research (IJSR)
Call for Papers | Fully Refereed | Open Access | Double Blind Peer Reviewed

ISSN: 2319-7064


Downloads: 145 | Views: 232 | Weekly Hits: ⮙1 | Monthly Hits: ⮙1

Research Paper | Biochemistry Science | India | Volume 4 Issue 5, May 2015


A Prognostic Study of MDA, Sod and Catalase in Breast Cancer Patients

Ankita Sahu | Meena Varma | Kamal Kachhawa


Abstract: Breast cancer is one of the most commonest cancer after the cervical cancer in Indian women. The balance between oxidant and antioxidant has been suggested as an important factor for initiation and progression of breast cancer. The aim of the study is to determine erythrocyte superoxide dismutase (SOD), catalase (CAT) activities as antioxidant enzymes and malondialdehyde (MDA) levels in women having breast cancer and compared it with age matched healthy control women. Superoxide Dismutase (SOD), Catalase, malondialdehyde (MDA) were assayed in 300 subject, in which 150 Breast Cancer patients and 150 healthy control. BMI was also measured in each of the patients and control groups. In this study, we found the SOD and CAT activities in breast cancer patients were significantly lower than control groups. Activities of malondialdehyde (MDA) was greater in patients compared with the control group which may reflect increased oxidative stress in the patient of breast cancer. The results of this study have shown a higher reactive oxygen species (ROS) production and decreased SOD and CAT activities, which support the oxidative stress hypothesis in carcinogenesis. This study was considered these enzymes as biomarker for early detection of recurrent the disease.


Keywords: Malondialdehyde MDA, Superoxide Dismutase SOD, Catalase CAT, Reactive Oxygen Species ROS, Breast Cancer


Edition: Volume 4 Issue 5, May 2015,


Pages: 157 - 159


How to Download this Article?

Type Your Valid Email Address below to Receive the Article PDF Link


Verification Code will appear in 2 Seconds ... Wait

Top